ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2009
Respiratory syncytial virus: diagnosis, treatment and prevention.
Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Antibiotic therapy versus no antibiotic therapy for children aged 2 to 59 months with WHO-defined non-severe pneumonia and wheeze.The Cochrane database of systematic reviews · 2021Pooled it
- Long-term stability of the GMP-compliant recombinant BCG vaccine against human RSV under quality control analyses.iScience · 2026Article
- A comprehensive look at Respiratory Syncytial Virus (RSV): from pathogenesis to prevention.Tropical diseases, travel medicine and vaccines · 2026Review
- Incidence, Complications, and Quality of Life in Adults ≥ 60 Years Old With Laboratory-Confirmed RSV Infections Attended in Primary Care and in Hospitals: A Study Over Three Seasons in Valladolid, Spain.Influenza and other respiratory viruses · 2026Observational
- Double-Stapled Peptide Scan Yields Potent Fusion Inhibitors of Respiratory Syncytial Virus.Journal of medicinal chemistry · 2026Article
- Advancements in Respiratory Syncytial Virus (RSV) Prevention and Treatment in Pediatrics.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Article
- Near-Source Wastewater Surveillance of SARS-CoV-2, Influenza A, and Respiratory Syncytial Virus With Spatiotemporal Evaluation of Pepper Mild Mottle Virus as a Fecal Indicator.Water environment research : a research publication of the Water Environment Federation · 2026Article
- Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged < 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Optimizing Timing for Respiratory Syncytial Virus Prevention Interventions for Infants.JAMA network open · 2025Article
- [Evaluation of the Predictive Performance of Pragmatic Models of Respiratory Syncytial Virus Transmission during Winter in the Republic of Korea].Jugan geon-gang gwa jilbyeong · 2025Article
- Severe pneumomediastinum in an infant with respiratory syncytial virus infection: A case report.Medicine · 2025Article
- Circulation of Respiratory Syncytial Virus (RSV) in Poland Between Seasons of 2009/2010 and 2022/2023 Based on SENTINEL System.Microorganisms · 2025Article
- A practical guidance on the prevention and treatment of childhood respiratory syncytial virus infection in Kurdistan.Frontiers in pediatrics · 2025Article
- Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain.Human vaccines & immunotherapeutics · 2024Article
- RSV Disease Burden in Older Adults: An Italian Multiregion Pilot Study of Acute Respiratory Infections in Primary Care Setting, Winter Season 2022-2023.Influenza and other respiratory viruses · 2024Article
- Safety, Tolerability, and Pharmacokinetics of Nebulized GB05-Human IFNα1b Inhalation Solution: A Randomized, Placebo-Controlled, Dose-Escalation Phase I Study in Healthy Chinese Adult Volunteers.Infectious diseases and therapy · 2024Article
- How Does the Burden of Respiratory Syncytial Virus Compare to Influenza in Spanish Adults?Influenza and other respiratory viruses · 2024Article
- Article
- Inhaled "Muco-Trapping" Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory Syncytial Virus (RSV) is a common virus that infects children and adults; however, children younger than two years of age tend to develop more serious respiratory symptoms. RSV is responsible for thousands of outpatient visits (e.g., emergency room/primary care physician), hospitalizations and can result in death. Treatment is primarily supportive care and the illness resolves without complications in most children. RSV prophylaxis with palivizumab is an option for high-risk infants and children, which can decrease hospitalization and length of stay. Immunocompromised patients are a special population of which ribavirin and palivizumab may be used for treatment. Currently, no medication or vaccine available has been able to show a reduction in mortality from RSV. Future vaccines are in the developmental stage and will hopefully decrease the symptomatic and economic burden of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.